Concurrent sessions
As cancer care becomes increasingly personalised, pharmacogenomic (PGx) screening has the potential to improve supportive care by reducing toxicity and tailoring treatments to individual patients. While the evidence base in oncology is growing, its application in supportive care remains emerging.
Uptake in practice is variable, limited by practical, system, and knowledge-based barriers, alongside a heterogeneous evidence base. Drawing on learnings from trial settings—including the Peter Mac PRECISION trial (~600 patients to date)—this session will highlight real-world challenges such as access to testing, workflow integration across centralised and remote care models, interpretation of results, and the role of multidisciplinary teams. Addressing these gaps will require both strengthening the evidence and embedding PGx within routine care systems.
Presented by a senior pharmacist from the Peter MacCallum Cancer Centre Pharmacogenomics Clinical Service, this session will provide a practical overview of PGx in supportive care. Attendees will gain insight into where PGx can add value and the changes needed to support implementation in everyday practice.
This session is run in collaboration with the Multinational Association of Supportive Care in Cancer (MASCC)